Last reviewed · How we verify
NCT05705973: NAGOMI COMPLEX
Ultimaster Nagomi™ Sirolimus Eluting Coronary Stent System in Complex PCI Patients
trial testing Ultimaster Nagomi™ in Cardiovascular Disease in 3,000 participants. Participants enrolled and being followed up; not accepting new ones.
29 April 2026
Quick facts
| Lead sponsor | Terumo Europe N.V. |
|---|---|
| Status | Active, enrolled |
| Study type | OBSERVATIONAL |
| Enrollment | 3,000 |
| Start date | 25 April 2023 |
| Primary completion | 29 April 2026 |
| Estimated completion | 29 April 2027 |
| Sites | 52 locations across France, Italy, Netherlands, Belgium, Austria, Serbia, Estonia, Ireland |
Drugs / interventions tested
- Ultimaster Nagomi™
Conditions studied
- Cardiovascular Disease — all drugs for Cardiovascular Disease →
- Coronary Artery Occlusion — all drugs for Coronary Artery Occlusion →
- Ischemic Heart Disease — all drugs for Ischemic Heart Disease →
Sponsor
Terumo Europe N.V.
Who can join
18 and older, any sex, with Cardiovascular Disease or Coronary Artery Occlusion. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The NAGOMI COMPLEX PMCF (Post-Market Clinical Follow-up) study has been designed to expand the knowledge about outcomes with the Ultimaster Nagomi™ sirolimus eluting coronary stent system (Ultimaster Nagomi™) in complex PCI subjects. The features for a complex PCI are based upon subgroup analysis of earlier published studies.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05705973
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cardiovascular Disease
Currently open trials in the same condition.
- NCT07238556 — A Novel Digital Tool Physicians Can Use to Prescribe Exercise to Patients With Cardiovascular Disease Risk Factors · NA · recruiting
- NCT07293260 — Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction - Coronary Computed Tomography Angiography Trial · Phase 3 · recruiting
- NCT07497932 — Nutritional Effects in Cardiovascular Surgery · NA · recruiting
- NCT06625073 — Randomized Trial of SGLT2i in Heart Transplant Recipients · Phase 4 · recruiting
- NCT06485700 — Peers and Technology for Adherence, Access, Accountability, and Analytics (PT4A) · NA · recruiting
Other Terumo Europe N.V. trials
Trials by the same sponsor.
- NCT05911633 — BioPearl™ Microspheres Loaded With Doxorubicin for the Treatment of Unresectable Hepatocellular Carcinoma (HCC) · NA · recruiting
- NCT05451862 — Holmium-166 Transarterial Radioembolization in Unresectable, Early Stage Hepatocellular Carcinoma. · NA · terminated
- NCT05111795 — Holmium-166 Retrospective Collection of Real-World Data · completed
- NCT05027698 — Post-Market Clinical Investigation of the FemoSeal™ VCS: A Prospective, Multi-Center Observational European Study · completed
- NCT04546477 — Prospective Multicenter Study to Confirm the Performance of the Renzan Stent in Treatment of SFA/POP Artery Disease · NA · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05705973 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Terumo Europe N.V.
- Last refreshed: 20 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05705973.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing